Furthermore, simvastatin-treated patients with AAA exhibited lower CyPA mRNA, as well as CyPA intracellular protein levels.34 Thus, the interference with signaling pathways leading to CyPA may reveal a new strategy in the treatment of AAA. The gene discussed is PPIA; the disease is triple-A syndrome.